Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291–329.
Article
CAS
Google Scholar
Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637–47.
Article
CAS
Google Scholar
Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257–71.
Article
CAS
Google Scholar
Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64(3):285–92.
Article
CAS
Google Scholar
Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270–82.
Article
CAS
Google Scholar
Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(8):982–91.
Article
Google Scholar
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–87.
Article
CAS
Google Scholar
McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98.
Article
CAS
Google Scholar
Mercuri E, Muntoni F, Osorio AN, Tulinius M, Buccella F, Morgenroth LP, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9(5):341–60.
Article
Google Scholar
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251–67.
Article
Google Scholar
Bach JR, Martinez D, Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil. 2010;89(8):620–4.
Article
Google Scholar
Pane M, Fanelli L, Mazzone ES, Olivieri G, D’Amico A, Messina S, et al. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord. 2015;25(10):749–53. https://doi.org/10.1016/j.nmd.2015.07.009.
Article
PubMed
PubMed Central
Google Scholar
Trucco F, Domingos JP, Tay CG, Ridout D, Maresh K, Munot P, et al. Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study. Chest. 2020;158(4):1606–16. https://doi.org/10.1016/j.chest.2020.04.043.
Article
CAS
PubMed
Google Scholar
Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87(2):149–55.
PubMed
Google Scholar
Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77(5):444–52.
Article
CAS
Google Scholar
Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9):e1003222. https://doi.org/10.1371/journal.pmed.1003222.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leiden Open Variation Database. The DMD gene homepage. 2021. https://www.dmd.nl/.
Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84(6):698–705.
Article
Google Scholar
Chesshyre M, Ridout D, Hashimoto Y, Ookubo Y, Torelli S, Maresh K, et al. Duchenne muscular dystrophy patients lacking the dystrophin isoforms Dp140 and Dp71 and mouse models lacking Dp140 have a more severe motor phenotype. medRxiv. 2021. https://doi.org/10.1101/2021.07.27.21261120v1.
Article
Google Scholar
Lidov HGW, Selig S, Kunkel LM. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 1995;4(3):329–35.
Article
CAS
Google Scholar
Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med. 1998;17(4):407–29.
Article
CAS
Google Scholar
Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347–61.
Article
Google Scholar
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445–55. https://doi.org/10.1016/S1474-4422(18)30026-7.
Article
PubMed
PubMed Central
Google Scholar
Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional challenges in duchenne muscular dystrophy. Nutrients. 2017;9:594.
Article
Google Scholar
Sarrazin E, Von Der Hagen M, Schara U, Von Au K, Kaindl AM. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2014;18(1):38–44. https://doi.org/10.1016/j.ejpn.2013.08.008.
Article
PubMed
Google Scholar
West NA, Yang ML, Weitzenkamp DA, Andrews J, Meaney FJ, Oleszek J, et al. Patterns of growth in ambulatory males with duchenne muscular dystrophy. J Pediatr. 2013. https://doi.org/10.1016/j.jpeds.2013.08.004.
Article
PubMed
PubMed Central
Google Scholar
Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123–31.
Article
CAS
Google Scholar
Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177–89.
Article
Google Scholar
Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048–55.
Article
CAS
Google Scholar
Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, et al. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy. Eur J Pediatr. 2019;178(5):633–40.
Article
CAS
Google Scholar
Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, et al. Fractures and linear growth in a nationwide cohort of boys with duchenne muscular dystrophy with and without glucocorticoid treatment: Results from the uk northstar database. JAMA Neurol. 2019;76(6):701–9.
Article
Google Scholar
Matsumoto M, Awano H, Lee T, Takeshima Y, Matsuo M, Iijima K. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup. Neuromuscul Disord. 2017;27(11):1023–8. https://doi.org/10.1016/j.nmd.2017.06.007.
Article
PubMed
Google Scholar
Villarreal-Silva M, Centeno-Cruz F, Suárez-Sánchez R, Garrido E, Cisneros B. Knockdown of Dystrophin Dp71 impairs PC12 cells cycle: localization in the spindle and cytokinesis structures implies a role for Dp71 in cell division. PLoS ONE. 2011;6(8):23504.
Article
Google Scholar
Benabdesselam R, Rendon A, Dorbani-Mamine L, Hardin-Pouzet H. Effect of Dp71 deficiency on the oxytocin hypothalamic axis in osmoregulation function in mice. Acta Histochem. 2019;121(3):268–76.
Article
CAS
Google Scholar
Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol Endocrinol Metab. 1995;268(1):E67–74. https://doi.org/10.1152/ajpendo.1995.268.1.E67.
Article
CAS
Google Scholar
Zatz M, Betti RT. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. Am J Med Genet. 1986;24(3):567–72.
Article
CAS
Google Scholar
Zatz M, Betti RTB, Frota-Pessoa O. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. Am J Med Genet. 1986;24(3):549–66.
Article
CAS
Google Scholar
Zatz M, Rapaport D, Vainzof M, De Cassia Pavanello MR, Rocha JML, Betti RTB, et al. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy. Am J Med Genet. 1988;31(4):821–33.
Article
CAS
Google Scholar
Bertoli S, Foppiani A, De Amicis R, Leone A, Mastella C, Bassano M, et al. Anthropometric measurement standardization for a multicenter nutrition survey in children with spinal muscular atrophy. Eur J Clin Nutr. 2019;73(12):1646–8.
Article
Google Scholar